Loading...
Docoh

Kinnate Biopharma (KNTE)

Utility
Inhibitors of Raf Kinases
14 Apr 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, Eric MURPHY, Jason COX, Robert KANIA
Filed: 11 Oct 21
Utility
Inhibitors of Raf Kinases
24 Mar 22
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY, Jason COX, Robert KANIA
Filed: 16 Sep 21
Utility
Inhibitors of Raf Kinases
30 Sep 21
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. KALDOR, Toufike KANOUNI, John TYHONAS, Eric MURPHY
Filed: 25 Mar 21
Utility
Inhibitors of RAF kinases
24 Aug 21
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Stephen W. Kaldor, Toufike Kanouni, John Tyhonas, Eric Murphy
Filed: 23 Oct 20
Utility
Inhibitors of Raf Kinases
12 Aug 21
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
Filed: 4 Feb 21
Utility
Inhibitors of Cyclin-dependent Kinases
6 May 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
Filed: 11 Nov 20
Utility
Inhibitors of Cyclin-dependent Kinases
25 Feb 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee ARNOLD, Stephen W. KALDOR, Eric A. MURPHY
Filed: 2 May 19
Utility
Inhibitors of RAF kinases
23 Feb 21
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. Kaldor, Toufike Kanouni, Lee Arnold
Filed: 30 Apr 20
Utility
Inhibitors of cyclin-dependent kinases
19 Jan 21
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike Kanouni, Lee D. Arnold, Stephen W. Kaldor, Eric A. Murphy, John Tyhonas
Filed: 28 Jun 19
Utility
Inhibitors of Raf Kinases
4 Nov 20
Provided herein are heteroaryl inhibitors of receptor tyrosine kinase effector (RAF), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of disease.
Stephen W. KALDOR, Toufike KANOUNI, Lee ARNOLD
Filed: 29 Apr 20
Utility
Inhibitors of Cyclin-dependent Kinases
22 Jan 20
Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
Toufike KANOUNI, Lee D. ARNOLD, Stephen W. KALDOR, Eric A. MURPHY, John TYHONAS
Filed: 27 Jun 19
  • 1
Patents are sorted by USPTO publication date, most recent first